Pharmamar SA, of Madrid, said it signed an agreement with Impilo Pharma, a part of Immedica Group, of Stockholm, for the exclusive promotion and distribution of its cancer compound, Yondelis (trabectedin), throughout the Nordic countries and Eastern Europe.